What happened

The AI model identified future pneumonitis risk from pretreatment CT patterns and showed strong performance across diverse external datasets, outperforming traditional risk models.

Why it matters

Early risk identification can guide closer monitoring and prevention, though results require larger prospective validation before routine clinical use.

Researchers at UT MD Anderson developed an AI tool (CIPHER) that analyzes pretreatment chest CT scans to identify which lung cancer patients may later develop pneumonitis, a potentially life-threatening inflammatory side effect. In testing, the model achieved an AUC of about 0.83 in both internal and external cohorts, outperforming conventional clinical-factor models and radiomics approaches.

The approach relied on patterns in lung tissue rather than seeking pneumonitis itself, suggesting routine imaging may reveal vulnerability beyond observable symptoms and known risk factors, with consistent performance despite scanner and protocol differences.

What this does not tell us

Prospective validation in larger, more diverse patient populations is needed before integration into routine clinical workflows.

FOR PEOPLE

Benefits reported

The evidence shows AI enables earlier identification of risk, expanding clinicians' ability to monitor and intervene.

FOR AI AND ITS OPERATORS

Benefits reported

The model demonstrates improved predictive performance on pre-treatment imaging, extending AI-driven risk assessment to a clinical workflow.

These are two separate readings of what the sources describe. Reported claims and risks do not by themselves establish a real-world effect.

Original sources · 1
  1. AI model uses routine imaging to identify patients at risk for serious treatment-induced lung inflammation ↗UT MD Anderson · 2026-09-24

Reporting discovered in United States. Discovery market does not mean the event happened there.